Compare Booking Holdings Inc (BKNG) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Booking Holdings Inc vs Summit Therapeutics Inc — how do they compare? Booking Holdings Inc trades at $178.4 (market cap $135.49B), while Summit Therapeutics Inc trades at $15.29 (market cap $12.01B). The key difference: Booking Holdings Inc is far larger — about 11.3× Summit Therapeutics Inc's market cap, and Booking Holdings Inc pays a 0.92% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| BKNG | SMMT | |
|---|---|---|
Market Cap | $135.49B | $12.01B |
Sector | Consumer Cyclical | Health |
52-Week High | $231.02 | $29.32 |
52-Week Low | $154.13 | $13.05 |
Enterprise Value | $138.41B | $11.43B |
Dividend Yield | 0.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Booking Holdings (BKNG) trades at $175.80, down 1.45% on the day, with a bearish technical signal but strong fundamentals including a 22.23% net income margin and consistent revenue growth. Recent earnings show mixed results with a Q1 2026 beat but a Q4 2025 miss, while analyst consensus remains strongly bullish with a $220.88 price target. The company maintains robust cash flow from operations at $9.41B for 2025 and continues to innovate in travel services, as highlighted by recent OpenTable initiatives.
The outlook for BKNG is positive based on solid profitability and growth prospects, though risks include high debt levels with a 64.02% debt-to-asset ratio and competitive pressures. Investment opportunity lies in its dominant market position and earnings potential, but investors should monitor execution risks and macroeconomic factors affecting travel demand.
Summit Therapeutics (SMMT) trades at $15.30, showing modest daily gains of 0.33%. The stock faces bearish technical signals with negative cash flows and substantial losses (-$1.08B net income in 2025). Recent developments include the sale of Phase III asset ridinilazole and positive clinical trial results for ivonescimab. Analyst sentiment remains optimistic with 67% buy ratings and a $15.57 consensus target, though financial metrics show concerning profitability with -270.95% ROE.
SMMT presents a high-risk, catalyst-driven opportunity with binary outcomes dependent on clinical success. The company's heavy reliance on ivonescimab development creates significant upside potential but also substantial execution risk. Negative cash flow trends and persistent losses require careful monitoring of upcoming Q2 2026 earnings and clinical milestones for directional clarity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Booking Holdings Inc
Booking is the world's largest online travel agency by revenue, offering booking and payment services for hotel and alternative accommodation rooms, airline tickets, rental cars, restaurant reservations, cruises, experiences, and other vacation packages. The company operates a number of branded travel booking sites, including Booking.com, Agoda, OpenTable, and Rentalcars.com, and has expanded into travel media with the acquisitions of Kayak and Momondo. Transaction fees for online bookings account for the bulk of revenue and profits.
Read more on BKNG →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
